PMID- 35385202
OWN - NLM
STAT- MEDLINE
DCOM- 20220608
LR  - 20220915
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Print)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 6
DP  - 2022 Jun
TI  - Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, 
      retrospective, 1 year real-life study.
PG  - e15489
LID - 10.1111/dth.15489 [doi]
LID - e15489
AB  - Several new biologic agents targeting IL23/Th17 axis, such as risankizumab, have 
      been developed for the treatment of psoriasis. The aim of the present study was 
      to analyze the efficacy and safety of risankizumab in patients with 
      moderate-to-severe psoriasis over a 52-week period. A multicentric retrospective 
      study was conducted in patients who initiated risankizumab between July 2019 and 
      December 2020. Psoriasis Area and Severity Index-PASI was measured at baseline 
      and after 4, 16, 28 and 52 weeks. Clinical responses were evaluated by PASI75, 
      PASI90 and PASI100 at the same timepoints. Potential safety issues and adverse 
      events (AEs) were collected. Univariable and multivariable logistic regressions 
      were performed for variables predicting clinical response. One hundred and twelve 
      patients with psoriasis were included. PASI90 response was achieved by 17.86% of 
      patients at week 4, 72.22% at week 16, 91.0% at week 28 and 95.24% at week 52 (as 
      observed analysis). No associations between the considered variables and the 
      efficacy endpoints were retrieved, influence of variables such as Body Mass Index 
      (BMI), baseline PASI or previous biologics were not shown. No serious safety 
      issues or discontinuations related to adverse events were reported. Risankizumab 
      showed high efficacy and a favorable safety profile, regardless of patient- and 
      disease-related factors.
CI  - (c) 2022 The Authors. Dermatologic Therapy published by Wiley Periodicals LLC.
FAU - Caldarola, Giacomo
AU  - Caldarola G
AUID- ORCID: 0000-0002-8837-9232
AD  - Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universita 
      Cattolica del Sacro Cuore, Rome.
AD  - UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione 
      Policlinico Universitario A. Gemelli - IRCCS, Rome.
FAU - Zangrilli, Arianna
AU  - Zangrilli A
AUID- ORCID: 0000-0003-4983-4420
AD  - Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
FAU - Bernardini, Nicoletta
AU  - Bernardini N
AUID- ORCID: 0000-0002-6295-3574
AD  - Department of Medical-Surgical Sciences and Biotechnologies, Dermatology Unit 
      "Daniele Innocenzi", Sapienza University of Rome, Rome, Italy.
FAU - Bavetta, Mauro
AU  - Bavetta M
AUID- ORCID: 0000-0001-7552-5176
AD  - Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
FAU - De Simone, Clara
AU  - De Simone C
AD  - Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universita 
      Cattolica del Sacro Cuore, Rome.
AD  - UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione 
      Policlinico Universitario A. Gemelli - IRCCS, Rome.
FAU - Graceffa, Dario
AU  - Graceffa D
AD  - Istituto Dermatologico San Gallicano - IRCCS, Rome, Italy.
FAU - Bonifati, Claudio
AU  - Bonifati C
AUID- ORCID: 0000-0001-7752-4337
AD  - Istituto Dermatologico San Gallicano - IRCCS, Rome, Italy.
FAU - Faleri, Sara
AU  - Faleri S
AD  - UOC DERMATOLOGIA dell'Ospedale di Belcolle, Viterbo, Italy.
FAU - Giordano, Domenico
AU  - Giordano D
AD  - NESMOS department, dermatology unit, Sant'Andrea hospital, University of Rome 
      Sapienza, Rome, Italy.
FAU - Mariani, Marco
AU  - Mariani M
AD  - Section of Hygiene, University Department of Health Sciences and Public Health, 
      Universita Cattolica del Sacro Cuore, Rome, Italy.
FAU - Micheli, Adriana
AU  - Micheli A
AD  - Unita di Dermatologia, Ospedale Nuovo Regina Margherita, Rome, Italy.
FAU - Moretta, Gaia
AU  - Moretta G
AUID- ORCID: 0000-0002-8839-5961
AD  - Istituto Dermopatico dell'Immacolata - IRCCS, Rome, Italy.
FAU - Pagnanelli, Gianluca
AU  - Pagnanelli G
AD  - Istituto Dermopatico dell'Immacolata - IRCCS, Rome, Italy.
FAU - Panasiti, Vincenzo
AU  - Panasiti V
AD  - Plastic and Reconstructive Surgery Unit, Campus Bio-Medico University, Rome, 
      Italy.
FAU - Provini, Alessia
AU  - Provini A
AD  - Istituto Dermopatico dell'Immacolata - IRCCS, Rome, Italy.
FAU - Richetta, Antonio
AU  - Richetta A
AD  - Unit of Dermatology, Department of Internal Medicine and Medical Specialties, 
      Sapienza University of Rome, Rome, Italy.
FAU - Peris, Ketty
AU  - Peris K
AD  - Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universita 
      Cattolica del Sacro Cuore, Rome.
AD  - UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione 
      Policlinico Universitario A. Gemelli - IRCCS, Rome.
FAU - Bianchi, Luca
AU  - Bianchi L
AD  - Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20220413
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Antibodies, Monoclonal)
RN  - 90ZX3Q3FR7 (risankizumab)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Humans
MH  - *Psoriasis/diagnosis/drug therapy
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
PMC - PMC9287038
OTO - NOTNLM
OT  - efficacy
OT  - interleukin-23
OT  - psoriasis
OT  - real-life
OT  - risankizumab
OT  - safety
COIS- The authors declare no conflict of interest.
EDAT- 2022/04/07 06:00
MHDA- 2022/06/09 06:00
PMCR- 2022/07/15
CRDT- 2022/04/06 12:17
PHST- 2022/02/11 00:00 [revised]
PHST- 2021/12/05 00:00 [received]
PHST- 2022/04/01 00:00 [accepted]
PHST- 2022/04/07 06:00 [pubmed]
PHST- 2022/06/09 06:00 [medline]
PHST- 2022/04/06 12:17 [entrez]
PHST- 2022/07/15 00:00 [pmc-release]
AID - DTH15489 [pii]
AID - 10.1111/dth.15489 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Jun;35(6):e15489. doi: 10.1111/dth.15489. Epub 2022 Apr 13.